2028 Biosimilars Pharmacy 
DrugBank
SEPTEMBER 26, 2024
Biosimilars Biosimilars, while highly similar to their reference biopharmaceuticals, offer distinct advantages that position them as preferred therapeutic options in many cases. This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles.
FDA Law Blog: Biosimilars
DECEMBER 3, 2023
CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028. The pharmacy prompt payment requirements from the CGDP will also apply to the Discount Program. Sunsetting of Coverage Gap Discount Program: The 70% coverage gap discount under the CGDP will continue until December 31, 2024.
Expert insights. Personalized for you.
69 
Let's personalize your content